Alcohol Abuse

Overview

Alcohol abuse encompasses a range of conditions including Alcoholism, Alcohol Use Disorder (AUD), Alcohol Dependence, and Binge Drinking. These conditions are characterized by excessive or uncontrolled consumption of alcohol, leading to significant health, social, and nutritional consequences.

• Alcoholism: Chronic disease involving uncontrolled drinking and preoccupation with alcohol.

• Alcohol Use Disorder (AUD): Medical diagnosis for problematic drinking causing distress or harm.

• Alcohol Dependence: Physical or psychological reliance on alcohol.

• Binge Drinking: Consuming 5 or more drinks (men) or 4 or more drinks (women) in about 2 hours, raising blood alcohol concentration (BAC) to ≥0.08 g/dL.

Standard Drink Equivalents

Understanding standard drink sizes is essential for assessing alcohol intake and risk.

Statistics and Prevalence

Alcohol use is widespread in the United States, with significant public health implications.

• In 2024, 85% of adults (21+) reported drinking alcohol at some point.

• 21.7% of people aged 18+ reported binge drinking in the past month.

Pathophysiology and Etiology

Mechanisms of Alcohol Action

Alcohol acts as a CNS depressant, primarily affecting neurotransmitter systems and metabolic pathways.

• Gamma-aminobutyric acid (GABA): Alcohol enhances GABA activity, leading to sedation and decreased anxiety.

• Glutamate: Alcohol decreases glutamate activity, impairing cognitive and motor functions.

• Metabolism: Alcohol is metabolized in the liver, primarily by alcohol dehydrogenase and aldehyde dehydrogenase.

Risk Factors

• Genetic and Biological Factors: Family history increases risk.

• Cultural Differences: Social norms influence drinking patterns.

• Mood and Substance Use Disorders: Comorbid psychiatric conditions increase vulnerability.

Clinical Manifestations

Effects of Alcohol Use

Alcohol can produce mild euphoria when used in moderation, but excessive use leads to significant health risks.

• Cravings: Strong desire to consume alcohol.

• Diminished Function: Impaired ability to perform daily activities.

• Life-Threatening Conditions: Risk of overdose, organ damage, and death.

Intoxication and Overdose

Chronic Use and Complications

Long-Term Effects

• Liver Disease: Cirrhosis, fatty liver, hepatitis.

• Myocardial Disease: Alcoholic cardiomyopathy.

• Erosive Gastritis: Inflammation and erosion of stomach lining.

• Pancreatitis: Inflammation of the pancreas.

• Cancers: Increased risk of oral, esophageal, liver, and breast cancers.

• Malnutrition: Especially Thiamine (B1) deficiency.

• Cross-tolerance: Tolerance to other CNS depressants.

• Inability to form new memories: Cognitive impairment.

• Blackouts: Periods of amnesia during intoxication.

Wernicke-Korsakoff Syndrome (WKS)

WKS is a severe neurological disorder associated with chronic alcohol use and thiamine deficiency.

• Wernicke Encephalopathy: Confusion, ataxia, nystagmus; acute and reversible with treatment.

• Korsakoff Syndrome: Amnesia, memory loss, inability to form new information, confabulation; often irreversible.

Treatment of Wernicke-Korsakoff Syndrome

• Early intervention is critical.

• IV Thiamine administration.

• Monitor and treat withdrawal symptoms.

• Encourage proper nutritional status and replace nutrients/electrolytes.

• Outpatient management with oral thiamine.

Alcohol Withdrawal Syndromes

Alcohol Withdrawal Syndrome

Withdrawal symptoms begin 6–24 hours after last drink and may resolve within 1–2 days, but can progress to severe complications.

• Agitation, anxiety, anorexia, nausea & vomiting, insomnia.

• Hyperthermia, hypertension, tachycardia, tremor (shakiness).

• May develop alcohol hallucinosis, withdrawal seizures, or delirium tremens.

Alcohol Withdrawal Delirium (Delirium Tremens, DTs)

• Occurs on days 2–3, but can appear up to 14 days after last drink.

• Symptoms: Hallucinations, disorientation, anxiety, uncontrolled shaking, hypertension, tachycardia, hyperthermia.

• Main goal of treatment: Avoid DTs and seizures.

Diagnostic Tests

Blood Alcohol Level (BAL) Measurement

• Breathalyzer: Measures BAL.

• At 0.10%: Voluntary motor action impaired.

• At 0.20–0.25%: Inability to remain upright.

• High tolerance at >0.10% without behavioral symptoms suggests physical dependence.

Treatment of Withdrawal

First Line Treatment

• Benzodiazepines: Clorazepate, Oxazepam, Diazepam, Lorazepam, Chlordiazepoxide.

Treatment Approaches

• Fixed schedule, symptom-triggered, or combination therapy.

• Assess severity using CIWA-Ar or WAS scales.

• Medications: Acamprosate, Disulfiram, Naltrexone.

Determining Treatment

• Assessment: Substance use history, medical history, physical exam, labs, vital signs, comorbidities.

• Ambulatory or inpatient detox (medically supervised).

Symptom Control and Supportive Care

• Treat comorbid illnesses.

• Correct metabolic imbalances (glucose, potassium, magnesium, phosphate).

• Supplement with thiamine, multivitamins, folate.

Pharmacological Management

Disulfiram (Antabuse)

• Classification: Alcohol abuse therapy adjunct.

• Action: Inhibits aldehyde dehydrogenase, causing unpleasant reactions if alcohol is consumed (flushing, nausea, palpitations).

• Therapeutic Effects: Promotes abstinence via aversion therapy.

• Dosage: 500 mg/day for 1–2 weeks, then 250 mg/day (up to 500 mg/day).

• Adverse Effects: Drowsiness, fatigue, headache, psychosis, metallic/garlic-like taste, erectile dysfunction, skin rash, neuropathy.

Nursing Considerations

• Do not administer within 12 hours of alcohol ingestion.

• Monitor for severe reactions (respiratory depression, arrhythmias, MI, CHF, death).

• Administer oxygen, monitor ECG and potassium if severe reaction occurs.

Patient/Family Teaching

• Inform about purpose and consequences of drinking alcohol during therapy.

• Avoid alcohol-containing products (mouthwash, medications).

• Report signs of hepatotoxicity (yellow eyes/skin, dark urine, light stools, severe stomach pain).

• Best for patients committed to abstinence after withdrawal.

Naltrexone (ReVia, Vivitrol)

• Classification: Alcohol abuse therapy adjunct.

• Action: Blocks opioid receptors, reducing rewarding effects of alcohol and cravings.

• Therapeutic Effects: Reduces alcohol-dependent behavior.

• Dosage: IM (Vivitrol) or PO (ReVia).

• Side Effects: Headache, dizziness, sleep disturbance, nausea, decreased appetite, abdominal pain, hepatic failure, increased LFTs.

• Contraindications: Opioid use, liver failure.

Additional Uses and Considerations

• Can treat opioid use disorder (wait 7–14 days after last opioid use).

• Not recommended for under 18 years.

• Not addictive, does not cause withdrawal symptoms.

• Monitor for suicidal thoughts or depression.

Patient Teaching

• Monitor for injection site reactions (cellulitis, induration, abscess).

• Report persistent or worsening reactions to healthcare provider.

Acamprosate (Campral)

• Delayed release enteric coated tablets.

• Action: Decreases cravings and withdrawal symptoms.

• Abstinence required to start treatment (typically 5 days after last drink).

• If relapse occurs, continue medication and consult provider.

• Side Effects: Headache, nausea, diarrhea, insomnia, dizziness, anxiety.

• Best for those in recovery who want to avoid drinking.

Lifespan Considerations

• Adolescents: Increased risk for long-term cognitive and developmental effects.

• Women: Higher risk for liver damage and cardiovascular effects at lower doses.

• Pregnant Women: Risk of fetal alcohol spectrum disorders.

• Older Adults: Increased sensitivity to alcohol, risk of falls, comorbidities.

Nursing Process

• Assessment: Evaluate substance use, medical history, and comorbidities.

• Diagnosis: Identify alcohol-related disorders and complications.

• Goals/Planning: Promote safety, abstinence, and recovery.

• Interventions:

  • Promote safety during acute withdrawal.

  • Promote safety in home settings.

  • Promote health self-esteem.

  • Provide patient education.

• Evaluation: Monitor progress and adjust care as needed.

Key Equations and Concepts

• Blood Alcohol Concentration (BAC): where is the distribution ratio (0.68 for men, 0.55 for women).

Example

If a male weighing 70 kg consumes 40 g of alcohol:

Additional info: BAC calculation is an estimate; actual BAC depends on metabolism, food intake, and other factors.